-
公开(公告)号：US20070092940A1
公开(公告)日：2007-04-26
申请号：US11233258
申请日：2005-09-22
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）
I <？in-line-formula description =“In-line Formulas”end =“尾”→其中p为1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US20110137017A1
公开(公告)日：2011-06-09
申请号：US12971197
申请日：2010-12-17
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US20090175865A1
公开(公告)日：2009-07-09
申请号：US12399241
申请日：2009-03-06
IPC分类号： A61K39/395 , C07K16/46 , A61P35/00
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？> where p是1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US07521541B2
公开(公告)日：2009-04-21
申请号：US11233258
申请日：2005-09-22
IPC分类号： C07K16/00
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？> where p是1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US07855275B2
公开(公告)日：2010-12-21
申请号：US12399241
申请日：2009-03-06
IPC分类号： C07K16/00
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US08614306B2
公开(公告)日：2013-12-24
申请号：US13591755
申请日：2012-08-22
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/18 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译： 本发明涉及抗因子D抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其生产及其在制备用于治疗与过量或不受控制的疾病和病症的组合物和药物的用途 补体激活。 这些抗体可用于疾病的诊断，预防和治疗。
-
公开(公告)号：US20070280931A1
公开(公告)日：2007-12-06
申请号：US11552445
申请日：2006-10-24
申请人： Yvonne Chen , Henry Lowman , Yves Muller
发明人： Yvonne Chen , Henry Lowman , Yves Muller
CPC分类号： C07K16/22 , A61K38/00 , B65H2801/87 , C07K16/00 , C07K16/005 , C07K16/24 , C07K2299/00 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.
摘要翻译： 公开了亲本抗体的抗体变体，其具有插入母体抗体的高变区中的一个或多个氨基酸，并且对靶抗原的结合亲和力比亲本抗体对抗原的结合亲和力强至少约两倍 。
-
公开(公告)号：US07192738B2
公开(公告)日：2007-03-20
申请号：US10936059
申请日：2004-09-08
申请人： Henry Lowman , Samantha Lien
发明人： Henry Lowman , Samantha Lien
CPC分类号： C07K14/71 , C07K14/65 , C12N15/62 , G01N2333/4745 , G01N2510/00
摘要： IGFBP-3 fusion proteins are provided that are useful, for example, in cell-based assays, as IGF antagonists, and in mapping IGF-I and IGF-II binding sites on other molecules such as wild-type IGFBP-3 and IGF agonist peptides identified by phage display. Methods for making such fusion proteins are also provided.
-
公开(公告)号：US20050148035A1
公开(公告)日：2005-07-07
申请号：US10936059
申请日：2004-09-08
申请人： Henry Lowman , Samantha Lien
发明人： Henry Lowman , Samantha Lien
IPC分类号： C07H21/04 , C07K14/31 , C07K14/47 , C07K14/65 , C07K14/71 , C12N1/21 , C12N15/62 , C12P21/04 , G01N33/574
CPC分类号： C07K14/71 , C07K14/65 , C12N15/62 , G01N2333/4745 , G01N2510/00
摘要： IGFBP-3 fusion proteins are provided that are useful, for example, in cell-based assays, as IGF antagonists, and in mapping IGF-I and IGF-II binding sites on other molecules such as wild-type IGFBP-3 and IGF agonist peptides identified by phage display. Methods for making such fusion proteins are also provided.
摘要翻译： 提供IGFBP-3融合蛋白，其可用于例如作为IGF拮抗剂的基于细胞的测定，以及在其它分子例如野生型IGFBP-3和IGF激动剂上映射IGF-1和IGF-II结合位点 通过噬菌体展示鉴定的肽。 还提供了制备这种融合蛋白的方法。
-
公开(公告)号：US20080199886A1
公开(公告)日：2008-08-21
申请号：US12019212
申请日：2008-01-24
申请人： Henry Lowman , Samantha Lien
发明人： Henry Lowman , Samantha Lien
IPC分类号： G01N33/53
CPC分类号： C07K14/71 , C07K14/65 , C12N15/62 , G01N2333/4745 , G01N2510/00
摘要： IGFBP-3 fusion proteins are provided that are useful, for example, in cell-based assays, as IGF antagonists, and in mapping IGF-I and IGF-II binding sites on other molecules such as wild-type IGFBP-3 and IGF agonist peptides identified by phage display. Methods for making such fusion proteins are also provided.
摘要翻译： 提供IGFBP-3融合蛋白，其可用于例如作为IGF拮抗剂的基于细胞的测定，以及在其它分子例如野生型IGFBP-3和IGF激动剂上映射IGF-I和IGF-II结合位点 通过噬菌体展示鉴定的肽。 还提供了制备这种融合蛋白的方法。
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.04 秒)
